A Randomized, Single-blind, Threefold Crossover, Single-center Study to Assess the Safety and the Effects of 1 mg and 5 mg BAY1193397 in Comparison to Placebo on Skin Capillary Blood Flow and Transcutaneous Oxygen Pressure After Single Dose in Type II Diabetic Patients With Peripheral Artery Disease

Next Previous
Trial Profile

A Randomized, Single-blind, Threefold Crossover, Single-center Study to Assess the Safety and the Effects of 1 mg and 5 mg BAY1193397 in Comparison to Placebo on Skin Capillary Blood Flow and Transcutaneous Oxygen Pressure After Single Dose in Type II Diabetic Patients With Peripheral Artery Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Feb 2018

At a glance

  • Drugs BAY 1193397 (Primary)
  • Indications Peripheral arterial disorders; Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Sponsors Bayer

    • Most Recent Events

    • 09 Feb 2018 Planned End Date changed from 30 Nov 2018 to 31 Oct 2018.
    • 08 Jun 2017 Status changed from not yet recruiting to recruiting.
    • 23 May 2017 Planned initiation date changed from 30 Apr 2017 to 24 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top